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Figure 1. Cumulative incidence of relapse according to CD4+ immune recon-
stitution in myeloid leukemia
Figure 2. Non-relapse mortality according to CD4+ immune reconstitution in
all patients271
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Background: Relapse of leukemia after pediatric hemato-
poietic cell transplantation (HCT) is a frequent cause of
treatment failure. Immune reconstitution (IR) early after HCT
is pivotal to generate a potent graft-versus-leukemia effect.
We studied the association between IR of various lympho-
cyte subsets and outcomes in children receiving a cord blood
HCT for hematological malignancies.
Methods: All consecutive patients with a hematological
malignancy receiving a cord blood HCT between 2004-2014
at Great Ormond Street Hospital London and at the UMC
Utrecht were included. Patients received a myeloablative
regimen  Thymoglobulin. Primary endpoint was relapse;
secondary endpoints were overall survival, non-relapse
mortality (NRM), acute GvHD (grade 2-4) and chronic GvHD.
Lymphocyte-subsets (CD3+, CD4+, CD8+, NK and B-cells)
weremonitored every other week after engraftment. Various
deﬁnitions of IR were analyzed including one in line with a
reported association: CD4+ T-cell count >50/mL in 2
consecutive measurements within 100 days post-HCT (Bar-
telink et al, BBMT 2013). Cox proportional hazardmodels and
logistic regression models were used.
Results: 89 patients were included, with a median age of 7.1
years (range0.7-18): 36ALL (19CR1,14CR2, 3 CR3), 49AML (14
refractory, 35 CR) and 4 other malignancies. 36 patients
received Thymoglobulin (Utrecht only). CD4-IR (count >50,
twice <100 days) was the best predictor for endpoints; in
multivariate (MV) analyses, CD4-IR was a predictor for lower
probability of relapse in AML patients (MV: HR 0.29, 95% CI
0.03-0.98, p¼0.04; ﬁgure 1), but not in ALL (p¼0.14). CD4-IR
was also a predictor for NRM (MV: HR 0.13, 95% CI 0.03-0.52,
p¼0.004; ﬁgure 2). CD4-IR predicted OS in AML (MV: HR
0.17, 95% CI 0.06-0.53, p¼0.002), but not in ALL. However,
CD4-IR did not have an impact on acute grade 2-4 (p¼0.41)
or chronic GvHD (p¼0.12). Successful CD4-IR was less
frequent in patients receiving Thymoglobulin (MV: OR 0.04,
95% CI 0.002-0.27, p¼0.005). Associations with the endpoints
for the other lymphocyte-subsets were less predictive.
Conclusion: Early CD4-IR post cord blood HCT predicts the
probability of relapse in AML as well as NRM in all patients.
Thymoglobulin negatively impacts CD4-IR post cord bloodHCT, hence the use and/or the dosing of Thymoglobulin
should be carefully re-considered.272
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Background: Grade III-IV toxicities in the 30 days post
allogeneic hematopoietic cell transplantation (alloHCT) is
correlated with higher transplant-related mortality (TRM) at
1 year in adults. Despite extensive literature in the ﬁeld there
remains a paucity of data on the incidence of grade III-IV
toxicities in children and adolescents undergoing alloHCT.
Methods: Retrospective cohort study of 166 patients (0.1-
22y) who underwent alloHCT from January 2000 and
December 2013 for malignant and non-malignant disease.
Patients were conditioned on 1 of 3 Busulfan (Bu)-based
conditioning regimens: reduced intensity (RIC): Bu(6.4-8mg/
kg)+ Fludarabine (Flu) [150mg/m2), reduced toxicity (RTC):
Bu(12.8-16mg/kg)+ Flu (180mg/m2) and myeloablative
(MAC): Bu(12.8-16mg/kg)+ cyclophosphamide (120-200mg/
kg) or melphalan (135mg/m2). Toxicities were scored using
the CTCAE grading system in the 30 days post-alloHCT.
Results: Median age at alloHCT was 8.5y (0.1-22y), malig-
nant n¼102, non-malignant n¼64. Median number of grade
III-IV toxicities in all groups was 3 (0-17). On univariate
analysis, age 12 (p¼0.002) was the single risk factor asso-
ciated with an increased incidence of grade III-IV toxicities in
the 30 days post-transplant. Incidence of toxicities was not
signiﬁcantly different in malignant v. non-malignant groups,
RIC v. RTC v. MAC regimens, donor, HLA, primary disease or
hematopoietic co-morbidity index. 1yr TRM in patients with
number of grade III-IV toxicities belowmedian (<3) was 2.6%
and 1yr TRM in those with above median ( 33) toxicities was
15.6% (p¼0.007). A total of 59 pediatric patients received
MAC regimens, n¼37<12y and n¼22 312. Of this cohort, 43%
of patients <12y and 72.7% of patients 312 had above median
number of grade III-IV toxicities (p¼0.034). 1 year TRM was
10.8% for <12y and 22.7% for 312y (p¼0.272). RIC and RTC
regimens were not associated with more than median tox-
icities in patients 312 yrs. Detailed information provided
below.
Conclusion: Despite recent advances in alloHCT, toxicity and
organ impairment remain a signiﬁcant cause of morbidity
and mortality during the ﬁrst year following alloHCT. Our
preliminary results suggest that higher incidence of grade III-
IV toxicities in the 30 days post-alloHCT correlates withGrade III-V toxicities Regimen
MAC (n/%)
59/36
RTC (n/%)
62/37
RIC (n/%)
45/27
Total (n/%)
166/100
Hepatic 18/30 13/20.97 16/35 47/28
Renal 4/6.78 0/0 4/8.9 8/4.8
Gastrointestinal 20/34 28/45.1 7/15 55/33
Hemorrhagic cystitis 5/8.5 6/9.7 0/0 11/6.6
Cardiac 3/5 1/1.6 1/2.2 5/3
Lungs 9/15 6/9.68 1/2.2 16/9.6
Sepsis 9/15 4/6.45 2/4.4 15/9
VOD 12/20 3/4.8 2/4.4 17/10.2
Total # toxicities 79 61 35 175higher risk of TRM at 1yr. Age 12y was signiﬁcantly corre-
lated with incidence of grade III-IV toxicities in the 30d post-
transplant. Prospective studies to validate our ﬁnding and
methods to decrease serious toxicities in adolescents are
warranted.273
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Background: Mucopolysaccharidosis type I-Hurler syn-
drome (MPS IH) is a lysosomal storage disease charac-
terized by multi-system morbidity and death in early
childhood. Hematopoietic cell transplantation (HCT) re-
sults in long-term survival, although with signiﬁcant re-
sidual disease burden. The effect of this disease burden on
the health-related quality of life of MPS IH patients after
HCT is however still unknown. Furthermore, little is
known about the perception of care of transplanted MPS
IH patients.
Methods: 63 alive and engrafted MPS IH patients, trans-
planted at one of the seven participating centers within
Europe were included in the study. The functional and psy-
chosocial health were evaluated using two validated ques-
tionnaires: the Child Health Questionnaire (CHQ) and
Pediatric Outcomes Data Collection Instrument (PODCI).
Subscale and summary scores were compared to normative
samples to derive z-scores and standard deviations (SD). The
inﬂuence of various patient, donor, transplantation as well as
disease-speciﬁc predictors was evaluated using univariate
and multivariate linear regression analysis. Correlation
analysis between the functional and psychosocial scores of
the CHQ and PODCI was performed using Spearman’s rank
correlation. The perception of care was evaluated by a third
validated questionnaire: the Measure of Processes of Care
(MPOC) questionnaire.
Results: The functional health of transplanted MPS IH
patients was signiﬁcantly diminished compared with
normative data; mean physical summary z-score -2.5 (SD
1.5), mean global functioning z-score -3.6 (SD 2.5) (ﬁgure 1
and 2). The psychosocial health appeared to be comparable
or only slightly reduced compared to normative data; mean
psychosocial summary z-score -0.1 (SD 1.3) (ﬁgure 1). A
higher obtained IDUA enzyme level after HCT predicted
for superior functional health, supporting the use of only
